Sun and colleagues first established the ENO1-YAP1/PLCB1/HPGD regulatory axis, demonstrating its glycolytic-independent mechanism in promoting tumor growth via arachidonic acid (AA) metabolic reprogramming. The gene discussed is HPGD; the disease is neoplasm.